MIRA Latest Press Releases

-- February 3, 2026 --

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study ACCESS Newswire 7:30 AM

-- October 24, 2025 --

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication ACCESS Newswire 7:30 AM

-- October 16, 2025 --

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain ACCESS Newswire 7:30 AM

-- September 30, 2025 --

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction ACCESS Newswire 7:30 AM

-- September 22, 2025 --

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog ACCESS Newswire 8:00 AM

-- September 16, 2025 --

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals ACCESS Newswire 7:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software